Covid19 Clinical Trial
— INFLAMMACOVOfficial title:
An Open Randomized Therapeutic Trial Using ANAKINRA, TOCILIZUMAB Alone or in Association With RUXOLITINIB in Severe Stage 2b and 3 of COVID19-associated Disease
COVID19-associated disease may have different clinical aspects classified in 3 stages. Some
patients initially presenting with a non-hypoxemic viral pneumonia (stage 2a) may evolve
toward a more severe stage 2b or 3 (acute respiratory distress syndrome, ARDS) around the 7th
or 10th day of evolution, with a severe biological inflammatory syndrome (CRP>200 mg/l), and
some times more severe complications such as acute renal insufficiency, consumptive
coagulopathy or shock, requiring increasing oxygen therapy, ICU admission, invasive
mechanical ventilation and possibly leading to death. This detrimental evolution is due to a
host-derived "cytokine storm" with a great excess of circulating inflammatory cytokines. In
animal models of ARDS complicating coronavirus or influenza virus infection, the cytokine
storm has been linked to hyperactivation of the NLRP3 inflammasome. NLRP3 constitutes an
intracellular protein platform which is responsible for caspase1 activation and processing of
interleukin (IL)-1beta and IL-18 . IL-1b is a major proinflammatory cytokine which induces
IL-6, whereas IL-18 is an inducer of interferon gamma (IFNg) production by Th-1 lymphocytes.
A blood IL-1/IL-6 signature can be defined by increased neutrophilia and CRP concentrations,
whereas an IL-18/IFNg signature is characterized by severe hyperferritinemia, consumptive
coagulopathy and cytopenia. A majority of patients with COVID-19 infections seems to have an
IL-1/IL-6 signature, evolving in the more severe forms toward an IL-18/IFNg signature,
mimicking cytokine profiles observed in other inflammatory diseases such as Still's disease
or hemophagocytic syndromes. In Still's disease, therapeutic inhibition of IL-1 or IL-6 has
proven to be very efficient strategies. During hemophagocytic syndromes, inhibition of IFNg
is effective in humans notably through blockade of its receptor signalization, using the JAK
kinase inhibitor ruxolitinib.
Following this strategy, we propose to use biological drugs currently available for
inhibition of IL-1 (anakinra), IL-6 (tocilizumab) or IFNg signaling (ruxolitinib) in the
severe forms of COVID19-associated disease. Our hypothesis is that IL-1, IL-6 or JAK kinase
inhibition will allow:
1. to prevent stage 2b worsening and the need to be admitted in ICU, by decreasing
oxygen-requirement and systemic inflammation
2. to improve stage 3 and extremely severe stage 3, allowing invasive mechanical
ventilation weaning, improving multi-system organ dysfunction, leading to a faster ICU
exit.
We propose an open randomized therapeutic trial (1/1/1) on 216 patients with severe stage 2b
and 3 of the disease
Status | Not yet recruiting |
Enrollment | 216 |
Est. completion date | November 1, 2022 |
Est. primary completion date | September 30, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility |
Inclusion Criteria: - Patients older than 18 year up to 75 year-old maximum - Eligible for resuscitation care in UCI - with proven infection with COVID-19, using at least one positive pharyngeal polymerase chain reaction (PCR) test - COVID19 infection pneumonia at - Stage 2b: Hypoxemic pneumonia (respiratory rate >30/min, Sat O2<90 mm Hg in ambient air) associated with a marked biological inflammatory syndrome (CRP>150mg/l) - or Stage 3: ARDS defined by a mechanically ventilated patient with a PaO2/FiO2 ratio < 300 for more than 24 hours. - or Advanced Stage 3: moderate to severe ARDS (PaO2/FiO2 < 200 to PEEP of at least 8 cmH2O) on invasive mechanical ventilation associated with another organ failure or syndrome among : 1) Shock with norepinephrine dosage > 3 mg/hour, 2) Acute renal oligo-anuric failure or requiring extra-renal lavage, 3) Hepatocellular failure or coagulopathy with factor V < 50%, 4) Myocarditis causing acute heart failure and/or shock. , 5) Hemophagocytic syndrome, 6) Hyperferritinemia > 5000 ng/mL Exclusion Criteria: - Patients younger than 18 or older than 75 year-old, - Pregnant or breastfeeding woman - Patient for whom measures of therapeutic limitations have been issued (non-admission to intensive care unit) - Patients treated with immunosuppressant/immunomodulators (Not only the concomitant administration of the following drugs prohibited in the protocol: other JAK inhibitors, corticosteroids, IL6 inhibitors). - Patient already included in another interventional therapeutic trial - Use of chronic oral corticosteroids > 10 mg prednisone equivalent per day for non-COVID-19 related disease - Uncontrolled autoimmune disease - Patients with active, suspected or known active systemic bacterial, viral (excluding COVID-19) or fungal infections that are not controlled (not only HIV, HBV or HCV infection and untreated bacterial or mycotic infection) - Patients with severe pre-existing uncontrolled organ dysfunction (heart, liver or kidney failure) not related to COVID-19 |
Country | Name | City | State |
---|---|---|---|
France | Assistance Publique Hôpitaux de Marseille | Marseille |
Lead Sponsor | Collaborator |
---|---|
Assistance Publique Hopitaux De Marseille |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Ventilation free days at D28 | number of days living without mechanical ventilation at D28 | 28 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05047692 -
Safety and Immunogenicity Study of AdCLD-CoV19-1: A COVID-19 Preventive Vaccine in Healthy Volunteers
|
Phase 1 | |
Recruiting |
NCT04395768 -
International ALLIANCE Study of Therapies to Prevent Progression of COVID-19
|
Phase 2 | |
Completed |
NCT04508777 -
COVID SAFE: COVID-19 Screening Assessment for Exposure
|
||
Completed |
NCT04506268 -
COVID-19 SAFE Enrollment
|
N/A | |
Terminated |
NCT04555096 -
A Trial of GC4419 in Patients With Critical Illness Due to COVID-19
|
Phase 2 | |
Completed |
NCT04961541 -
Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04546737 -
Study of Morphological, Spectral and Metabolic Manifestations of Neurological Complications in Covid-19 Patients
|
N/A | |
Terminated |
NCT04581915 -
PHRU CoV01 A Trial of Triazavirin (TZV) for the Treatment of Mild-moderate COVID-19
|
Phase 2/Phase 3 | |
Terminated |
NCT04542993 -
Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy
|
Phase 2 | |
Completed |
NCT04532294 -
Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants
|
Phase 1 | |
Completed |
NCT04494646 -
BARCONA: A Study of Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19)
|
Phase 2 | |
Not yet recruiting |
NCT04543006 -
Persistence of Neutralizing Antibodies 6 and 12 Months After a Covid-19
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Completed |
NCT04537663 -
Prevention Of Respiratory Tract Infection And Covid-19 Through BCG Vaccination In Vulnerable Older Adults
|
Phase 4 | |
Not yet recruiting |
NCT04527211 -
Effectiveness and Safety of Ivermectin for the Prevention of Covid-19 Infection in Colombian Health Personnel
|
Phase 3 | |
Completed |
NCT04387292 -
Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic
|
N/A | |
Completed |
NCT04979858 -
Reducing Spread of COVID-19 in a University Community Setting: Role of a Low-Cost Reusable Form-Fitting Fabric Mask
|
N/A | |
Not yet recruiting |
NCT05038449 -
Study to Evaluate the Efficacy and Safety of Colchicine Tablets in Patients With COVID-19
|
N/A | |
Completed |
NCT04610502 -
Efficacy and Safety of Two Hyperimmune Equine Anti Sars-CoV-2 Serum in COVID-19 Patients
|
Phase 2 | |
Active, not recruiting |
NCT06042855 -
ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin)
|
Phase 3 |